Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
1.110
-0.030 (-2.64%)
Nov 4, 2024, 4:00 PM EST - Market closed

Processa Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 2018 - 2015
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 2018 - 2015
Selling, General & Admin
4.915.668.764.693.261.61
Upgrade
Research & Development
6.885.811.496.883.172.32
Upgrade
Operating Expenses
11.7911.4620.2611.576.443.94
Upgrade
Operating Income
-11.79-11.46-20.26-11.57-6.44-3.94
Upgrade
Interest Expense
-----0.28-0.04
Upgrade
Interest & Investment Income
0.260.340.10.0100.01
Upgrade
EBT Excluding Unusual Items
-11.53-11.12-20.16-11.56-6.71-3.96
Upgrade
Asset Writedown
---7.27---
Upgrade
Other Unusual Items
---0.16--
Upgrade
Pretax Income
-11.53-11.12-27.42-11.96-15.41-3.96
Upgrade
Income Tax Expense
----0.53-1-0.6
Upgrade
Net Income
-11.53-11.12-27.42-11.43-14.41-3.36
Upgrade
Preferred Dividends & Other Adjustments
----4.630.51
Upgrade
Net Income to Common
-11.53-11.12-27.42-11.43-19.04-3.86
Upgrade
Shares Outstanding (Basic)
311100
Upgrade
Shares Outstanding (Diluted)
311100
Upgrade
Shares Change (YoY)
117.51%62.83%5.16%104.27%35.72%3.63%
Upgrade
EPS (Basic)
-4.55-8.48-34.05-14.92-50.77-13.99
Upgrade
EPS (Diluted)
-4.55-8.48-34.05-14.92-50.77-13.99
Upgrade
Free Cash Flow
-11.12-8.07-9.61-8.72-3.14-2.75
Upgrade
Free Cash Flow Per Share
-4.39-6.15-11.92-11.38-8.38-9.95
Upgrade
EBITDA
-11.79-11.46-19.47-10.78-5.63-3.13
Upgrade
D&A For EBITDA
000.790.790.80.8
Upgrade
EBIT
-11.79-11.46-20.26-11.57-6.44-3.94
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.